Northwest Biotherapeutics Inc
Northwest Biotherapeutics, Inc., a biotechnology company, focuses on developing personalized immune therapies for cancer. The company develops DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product candidate is the DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain can… Read more
Northwest Biotherapeutics Inc (NWBO) - Total Assets
Latest total assets as of September 2025: $30.61 Million USD
Based on the latest financial reports, Northwest Biotherapeutics Inc (NWBO) holds total assets worth $30.61 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Northwest Biotherapeutics Inc - Total Assets Trend (2000–2024)
This chart illustrates how Northwest Biotherapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Northwest Biotherapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Northwest Biotherapeutics Inc's total assets of $30.61 Million consist of 15.2% current assets and 84.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 8.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.29 Million | 4.8% |
| Goodwill | $626.00K | 2.3% |
Asset Composition Trend (2000–2024)
This chart illustrates how Northwest Biotherapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Northwest Biotherapeutics Inc's current assets represent 15.2% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 8.1% of total assets in 2024, down from 8.9% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2000.
- Asset Diversification: The largest asset category is intangible assets at 4.8% of total assets.
Northwest Biotherapeutics Inc Competitors by Total Assets
Key competitors of Northwest Biotherapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Northwest Biotherapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Northwest Biotherapeutics Inc generates 0.05x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Northwest Biotherapeutics Inc is currently not profitable relative to its asset base.
Northwest Biotherapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.08 | 0.09 | 0.04 |
| Quick Ratio | 0.08 | 0.09 | 0.04 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-80.71 Million | $ -54.37 Million | $ -366.91 Million |
Northwest Biotherapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Northwest Biotherapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 11.82 |
| Asset Growth Rate (YoY) | -4.1% |
| Total Assets | $26.73 Million |
| Market Capitalization | $316.05 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Northwest Biotherapeutics Inc's assets at a significant premium ( 11.82x), suggesting investors see substantial growth potential or unique competitive advantages.
Slight Asset Contraction: Northwest Biotherapeutics Inc's assets decreased by 4.1% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Northwest Biotherapeutics Inc (2000–2024)
The table below shows the annual total assets of Northwest Biotherapeutics Inc from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $26.73 Million | -4.08% |
| 2023-12-31 | $27.86 Million | -11.04% |
| 2022-12-31 | $31.32 Million | -22.00% |
| 2021-12-31 | $40.16 Million | +22.07% |
| 2020-12-31 | $32.90 Million | +260.38% |
| 2019-12-31 | $9.13 Million | -62.99% |
| 2018-12-31 | $24.67 Million | -49.56% |
| 2017-12-31 | $48.91 Million | -7.56% |
| 2016-12-31 | $52.91 Million | -25.27% |
| 2015-12-31 | $70.80 Million | +21.14% |
| 2014-12-31 | $58.44 Million | +211.12% |
| 2013-12-31 | $18.78 Million | +148.14% |
| 2012-12-31 | $7.57 Million | +3470.75% |
| 2011-12-31 | $212.00K | -27.89% |
| 2010-12-31 | $294.00K | +185.44% |
| 2009-12-31 | $103.00K | -93.04% |
| 2008-12-31 | $1.48 Million | -83.00% |
| 2007-12-31 | $8.71 Million | +1627.38% |
| 2006-12-31 | $504.00K | -20.13% |
| 2005-12-31 | $631.00K | +13.08% |
| 2004-12-31 | $558.00K | -35.94% |
| 2003-12-31 | $871.00K | -88.50% |
| 2002-12-31 | $7.57 Million | -61.12% |
| 2001-12-31 | $19.48 Million | +320.74% |
| 2000-12-31 | $4.63 Million | -- |